Molecular features, markers, drug targets, and prospective targeted therapeutics in cardiac myxoma

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Sporadic cardiac myxoma (CM) treatment primarily relies on surgical excision, with limited targeted therapeutic options.
• The underlying molecular mechanisms of CM pathogenesis are not fully understood, hindering drug target identification.
• Current research focuses on compiling structured data on CM pathophysiology, potential targets, and targeting molecules.

Purpose of the Study:

• To review current data on targeted and personalized medicine for cardiac myxoma.
• To discuss critical issues in developing novel therapeutic strategies for CM.
• To highlight progress in identifying molecular pathways and drug targets for CM.

Main Methods:

• Analysis of five critical disease pathways implicated in CM pathogenesis.
• Identification and mapping of 15-20 potential drug targets and their corresponding targeting molecules.
• Review of existing literature on CM pathophysiology and therapeutic interventions.

Main Results:

• Five key disease pathways involving seven functional groups associated with CM pathogenesis have been identified.
• A preliminary map of 15-20 drug targets and targeting molecules has been established.
• The study lays groundwork for patient stratification into targeted therapeutic regimens.

Conclusions:

• Targeted drug discovery holds promise for improving CM treatment efficacy.
• Understanding CM molecular profiles is crucial for developing personalized medicine approaches.
• Further research into CM pathogenesis is essential for advancing therapeutic strategies.